It was also reported that the administration of anti-IL-17A antibodies ameliorated the symptoms of EAE, GPI-induced arthritis, and IL-23-induced dermatitis in mice [29–31], and clinical trials of anti-IL-17A antibodies, such as secukinumab and ixekizumab, revealed that the neutralization of IL-17A was successful as a therapy for psoriasis and ankylosing spondylitis (AS) in humans [32–34]. The gene discussed is IL17A; the disease is arthritic joint disease.